000046973 001__ 46973
000046973 005__ 20200221144243.0
000046973 0247_ $$2doi$$a10.1016/j.tube.2015.10.010
000046973 0248_ $$2sideral$$a93398
000046973 037__ $$aART-2016-93398
000046973 041__ $$aeng
000046973 100__ $$0(orcid)0000-0001-7897-9173$$aAguilo, N.$$uUniversidad de Zaragoza
000046973 245__ $$aMTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice
000046973 260__ $$c2016
000046973 5060_ $$aAccess copy available to the general public$$fUnrestricted
000046973 5203_ $$aDevelopment of novel more efficient preventive vaccines against tuberculosis (TB) is crucial to achieve TB eradication by 2050, one of the Millennium Development Goals (MDG) for the current century. MTBVAC is the first and only live attenuated vaccine based on a human isolate of Mycobacterium tuberculosis developed as BCG-replacement strategy in newborns that has entered first-in-human adult clinical trials. In this work, we characterize the safety, immunogenicity and protective efficacy of MTBVAC in a model of newborn C57/BL6 mice. Our data clearly indicate that MTBVAC is safe for newborn mice, and does not affect animal growth or organ development. In addition, MTBVAC-vaccinated mice at birth showed enhanced immunogenicity and better protection against M. tuberculosis challenge in comparison with BCG.
000046973 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/BIO2014-5258P$$9info:eu-repo/grantAgreement/ES/MINECO/BIO2011-23555$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 643381-TBVAC2020$$9info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020$$9info:eu-repo/grantAgreement/EC/FP7/241745/EU/Discovery and preclinical development of new generation tuberculosis vaccines/NEWTBVAC$$9info:eu-repo/grantAgreement/ES/FECYT/INNOCASH-INC-098
000046973 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000046973 590__ $$a2.873$$b2016
000046973 591__ $$aMICROBIOLOGY$$b53 / 124 = 0.427$$c2016$$dQ2$$eT2
000046973 591__ $$aRESPIRATORY SYSTEM$$b23 / 59 = 0.39$$c2016$$dQ2$$eT2
000046973 591__ $$aIMMUNOLOGY$$b82 / 150 = 0.547$$c2016$$dQ3$$eT2
000046973 592__ $$a1.224$$b2016
000046973 593__ $$aImmunology$$c2016$$dQ2
000046973 593__ $$aMicrobiology (medical)$$c2016$$dQ2
000046973 593__ $$aMicrobiology$$c2016$$dQ2
000046973 593__ $$aInfectious Diseases$$c2016$$dQ2
000046973 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000046973 700__ $$0(orcid)0000-0001-7866-2803$$aUranga, S.$$uUniversidad de Zaragoza
000046973 700__ $$0(orcid)0000-0001-8644-120X$$aMarinova, D.$$uUniversidad de Zaragoza
000046973 700__ $$0(orcid)0000-0002-2787-9671$$aMonzon, M.$$uUniversidad de Zaragoza
000046973 700__ $$0(orcid)0000-0002-7173-7216$$aBadiola, J.$$uUniversidad de Zaragoza
000046973 700__ $$0(orcid)0000-0003-2993-5478$$aMartin, C.$$uUniversidad de Zaragoza
000046973 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología
000046973 7102_ $$11003$$2443$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Histología
000046973 7102_ $$11009$$2773$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Sanidad Animal
000046973 7102_ $$11008$$2X$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cProy. investigación HQA
000046973 773__ $$g96 (2016), 71-74$$pTUBERCULOSIS$$tTUBERCULOSIS$$x1472-9792
000046973 8564_ $$s529840$$uhttps://zaguan.unizar.es/record/46973/files/texto_completo.pdf$$yVersión publicada
000046973 8564_ $$s109105$$uhttps://zaguan.unizar.es/record/46973/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000046973 909CO $$ooai:zaguan.unizar.es:46973$$particulos$$pdriver
000046973 951__ $$a2020-02-21-13:23:07
000046973 980__ $$aARTICLE